Viking Therapeutics, Inc. (VKTX)
Develops experimental drugs to treat obesity, liver disease, and metabolic disorders.
$33.86-0.03%Healthcare
StockGlow Score
Bullish
BearishBullish
1 year ago+3.6%
The outlook
Viking Therapeutics is trading near its 50- and 200-day moving averages with analyst consensus strongly bullish across 19 firms. The stock sits roughly midway in its 52-week range, and the average analyst price target sits significantly above the current price. Overall sentiment leans decidedly bullish based on current data.
What’s behind the score
Analyst consensusStrong Buy — 1.4 avg of 19 analysts
Price trendAbove its 50- & 200-day averages
52-week range54% of the way from its 52-week low to high
Price targetAvg target +173% vs current price
Analyst price target
~12-month · 19 analysts$92.58average target+173.4% vs now
Now $33.86
Low $34.00High $125.00
Published targets from Wall Street analysts (public data) — what analysts expect over roughly a year. This is not a StockGlow forecast and not a recommendation. Analyst targets are frequently wrong.
Market cap
$3.93B
52-wk high
$43.15
52-wk low
$22.96
50-day avg
$33.75
200-day avg
$33.81
Trailing P/E
—